



**VIJAYA  
DIAGNOSTIC  
CENTRE**

May 26, 2022

To,  
Listing Department  
National Stock Exchange of India Limited,  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051  
Company Code No. VIJAYA

To,  
The Corporate Relations Department  
BSE Limited,  
Phiroz Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street  
Mumbai- 400 001  
Company Code No. 543350

Dear Sir/Madam,

**Sub: Intimation of Press Release.**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the "Press Release".

Please take the information on record.

Thanking you,

**For Vijaya Diagnostic Centre Limited**

**Anusha Kanumuru  
Company Secretary**





**VIJAYA  
DIAGNOSTIC  
CENTRE**

Regd. Office - 3-6-16 & 17, Street # 19, Himayath Nagar, Hyderabad-29, Telangana

## Vijaya Diagnostic Centre Limited posts strong performance with 23% growth in Revenues and 30% growth in PAT for FY22

**Hyderabad, May 26, 2022:** Vijaya Diagnostic Centre Limited (NSE: VIJAYA, BSE: 543350) one of the India's leading integrated diagnostic chain has announced its financial results for the quarter and twelve months ended 31<sup>st</sup> March 2022.

### Consolidated Financial Performance:

Particulars (Rs. Mn)	FY22	FY21	YoY	Q4FY22	Q4FY21	YoY
Revenue from Operations	4,624	3,767	23%	1,162	1,120	4%
EBITDA	2,037	1,660	23%	479	544	-12%
EBITDA Margin (%)	44.1%	44.1%		41.2%	48.6%	
Profit after Tax	1,097	845	30%	237	314	-25%

### Performance Highlights FY22 vs. FY21:

- Revenue from Operations increased by 23% YoY to Rs. 4,624 Mn
- Non-COVID revenue grew by 26% YoY from Rs. 3,124 Mn in FY21 to Rs. 3,930 Mn in FY22 while COVID & COVID allied revenue (RT-PCR, Antibody tests and COVID allied tests like IL-6 and D-Dimer) increased by 8% YoY to Rs. 694 Mn
- Revenue from B2C segment stood at 94% of total revenue
- EBITDA stood at Rs. 2,037 Mn, an increase of 23% over corresponding previous period; EBITDA margin was 44.1%
- PAT increased by 30% YoY to Rs. 1,097 Mn vs. Rs. 845 Mn in the corresponding previous period. PAT margin stood at 23.7%
- The company added 15 new centres including 3 hub centres and 1 reference lab, taking the total centre count to 95 and the total reference lab count to 12 as on 31<sup>st</sup> March 2022
- The Board has recommended a final dividend of Re. 1 per share (100% on a face value of Re. 1 per share) for the financial year ending 31<sup>st</sup> March 2022

### Performance Highlights Q4FY22 vs. Q4FY21:

- Revenue from Operations increased by 4% YoY to Rs. 1,162 Mn
- COVID & COVID allied revenue (RT-PCR, Antibody tests and COVID allied tests like IL-6 and D-Dimer) increased 54% YoY to Rs. 179 Mn due to COVID third wave, which impacted Non-COVID business. Non-COVID revenue declined marginally by 2% YoY to Rs. 983 Mn
- EBITDA stood at Rs. 479 Mn and EBITDA margin for the quarter was 41.2%
- PAT stood at Rs. 237 Mn and PAT margin for the quarter was 20.4%

**Commenting on the performance Ms. Suprita Reddy, CEO said,** *"I am happy to say that the company has been able to battle headwinds caused by multiple covid waves and was able to sustain business performance this year. The last financial year was one of great achievements for the company, marked by fulfilment of many crucial milestones – Opening up of 15 centres, which is by far the maximum number of centres we opened in a single year, serviced over 3.6 Mn customers, achieving an EBIDTA of over Rs. 200 crore and a PAT of over Rs. 100 Crore.*

*Though the last quarter was challenging due to the onslaught of the third covid wave which significantly impacted our non-covid business from the beginning of the January till the first half of February, we moved forward with positivity and confidence to expand our footprint by 6 new and fully equipped centres.*

*Vijaya has risen to stand out as the largest and most trusted provider of integrated diagnostic services, offering the whole gamut of high quality pathology and radiology all under one roof. We have always been particular about adopting the latest and the most advanced medical technology, procuring sophisticated equipment and building a brand of trust for our customers. Our business was always driven by a B2C strategy, way ahead of our competitors in the diagnostic space. With these being our inherent strengths, we are convinced that we will be able to successfully withstand the test of time and emerge as a brand of choice for our customers."*

**-END-**

**About Us:**

Vijaya Diagnostic Centre Limited (VDCL), is the largest integrated diagnostic chain having dominant presence in Southern India. Vijaya provides one-stop solution for pathology and radiology testing services to customers through extensive operational network, which consists of 95 diagnostic centres and 12 reference laboratories across 16 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata. The Company offers comprehensive range of diagnostic services from Basic pathology to high-end radiology.

**Corporate Identification No:** U85195TG2002PLC039075

**Regd. Office:** 3-6-16 & 17, Street # 19, Himayath Nagar, Hyderabad-29, Telangana

---

**For more information, please visit [www.vijayadiagnostic.com](http://www.vijayadiagnostic.com) OR contact:**

---

**Mr. Siva Rama Raju**

Head of Strategy

Vijaya Diagnostic Centre Limited

Tel: +91 90597 00749 / +91 99485 95555

Email: [sivaramaraju.v@vijayadiagnostic.in](mailto:sivaramaraju.v@vijayadiagnostic.in)  
[ir@vijayadiagnostics.in](mailto:ir@vijayadiagnostics.in)

**Anoop Poojari / Devrishi Singh**

CDR India

Tel: +91 98330 90434 / +91 98205 30918

Email: [anoop@cdr-india.com](mailto:anoop@cdr-india.com)  
[devrishi@cdr-india.com](mailto:devrishi@cdr-india.com)

**DISCLAIMER:**

*Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, import duties, litigation, labour relations etc. Actual results might differ substantially from those expressed or implied. Vijaya Diagnostic Centre Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*